Quick Answer
Edgewise Therapeutics, Inc. reported Stockholders Equity of $522.26 million for fiscal year 2025.
Edgewise Therapeutics, Inc. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $522.26M | +13.7% |
| 2024 | $459.22M | +44.0% |
| 2023 | $318.83M | -8.0% |
| 2022 | $346.72M | +26.4% |
| 2021 | $274.38M | +921.0% |
| 2020 | -$33.42M | -98.3% |
| 2019 | -$16.85M | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $558.65M | +14.3% | -5.2% |
| June 30, 2025 | $589.07M | +15.4% | +37.1% |
| March 31, 2025 | $429.72M | -19.7% | -6.4% |
| December 31, 2024 | $459.22M | +44.0% | -6.1% |
| September 30, 2024 | $488.88M | +68.3% | -4.2% |
| June 30, 2024 | $510.47M | +63.9% | -4.6% |
| March 31, 2024 | $534.94M | +62.7% | +67.8% |
| December 31, 2023 | $318.83M | -8.0% | +9.8% |
- Edgewise Therapeutics, Inc. showed an increase of +13.7% in Stockholders Equity compared to the prior fiscal year.
- Over the 2019–2025 period, Edgewise Therapeutics, Inc.’s stockholders equity has grown by 3198.9% (from -$16.85 million to $522.26 million).
- The most recent figure is from Edgewise Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: